Sunesis Pharmaceuticals to Present at BIO CEO and Investor Conference
SOUTH SAN FRANCISCO, Calif., Feb 10, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that Daniel N. Swisher, Jr., Chief Executive Officer and President, will present a company update at the 8th Annual BIO CEO and Investor Conference. The presentation will take place on Tuesday, February 14, 2006 at 11:30 a.m. at the Waldorf Astoria in New York City.
Interested parties may access a webcast of the presentation by visiting the Sunesis website at http://ir.sunesis.com . A replay of the webcast will be archived on the "Calendar of Events" page in the Investors and Media section of the Sunesis website for two weeks until February 28, 2006.
About Sunesis Pharmaceuticals
Sunesis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. Sunesis has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. Sunesis is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. For further information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com .
This press release may contain forward-looking statements that involve substantial risks and uncertainties. Sunesis may not actually achieve the plans, intentions or expectations contained in such forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations contained in such forward-looking statements. Sunesis does not assume any obligation to update any such forward-looking statements.
SOURCE Sunesis Pharmaceuticals, Inc.
investors, Eric Bjerkholt, CFO of Sunesis Pharmaceuticals, Inc., +1-650-266-3717; or media, Karen L. Bergman or Michelle Corral of BCC Partners, +1-650-575-1509, or +1-415-794-8662
Copyright (C) 2006 PR Newswire. All rights reserved.
News Provided by COMTEX